Sort   by:  
 Page size 
UnknownPhase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane.
Not available
S-EPMC4463422 | biostudies-literature
UnknownGenomic analysis reveals that immune function genes are strongly linked to clinical outcome in the North Central Cancer Treatment Group n9831 Adjuvant Trastuzumab Trial.
Not available
S-EPMC4334774 | biostudies-literature
UnknownFour-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31.
Not available
S-EPMC3164242 | biostudies-literature
UnknownSequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer.
Not available
S-EPMC3236650 | biostudies-literature
UnknownTrastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831.
Not available
S-EPMC4226805 | biostudies-literature
UnknownSurgical Excision Without Radiation for Ductal Carcinoma in Situ of the Breast: 12-Year Results From the ECOG-ACRIN E5194 Study.
Not available
S-EPMC4652014 | biostudies-literature
UnknownLong-Term Follow-Up of the E1199 Phase III Trial Evaluating the Role of Taxane and Schedule in Operable Breast Cancer.
Not available
S-EPMC4500829 | biostudies-literature
UnknownNeuropathy is not associated with clinical outcomes in patients receiving adjuvant taxane-containing therapy for operable breast cancer.
Not available
S-EPMC3732004 | biostudies-literature
UnknownImpact of PTEN protein expression on benefit from adjuvant trastuzumab in early-stage human epidermal growth factor receptor 2-positive breast cancer in the North Central Cancer Treatment Group N9831 trial.
Not available
S-EPMC3731983 | biostudies-literature
UnknownPrognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199.
Not available
S-EPMC4162494 | biostudies-literature
Sort   by:  
 Page size